Navigation Links
AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
Date:3/1/2012

IRVINE, Calif., March 1, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that it has initiated the first shipment of AHRO-001 Active Pharmaceutical Ingredient (API) to its research and development partner CardioNova, Ltd., a Russia based biotech company responsible for Phase 1 and 2 human clinical studies of AHRO-001. The clinical-grade material will be used to commence the toxicology studies conducted for Russian regulatory purposes.

"We are pleased to announce this first shipment, clearly a milestone for us in the development of AHRO-001 for use in upcoming human clinical studies," said AtheroNova CEO Thomas Gardner. "This is the highest purity ever achieved in AHRO-001 and is ready to be used in an advanced clinical setting for the first time. As we proceed through our clinical phases, we are extremely gratified to adhere to our aggressive development path and look forward to additional development milestones in the coming months."

"CardioNova is very excited to receive the first shipment," commented CardioNova CEO Andrey Boldyrev. "We are looking forward to starting the toxicology studies and initiating clinical studies in close cooperation with AtheroNova, who proves to be an ideal partner for this project. We believe that an effective partnership of our two companies will allow us to bring to market a novel drug that is much anticipated by doctors and patients all over the world."

About AHRO-001
AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain natural compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are the
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Announces a New Board Member
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
5. GenVec Achieves Second Milestone in Collaboration
6. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
7. MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row
8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
9. New compact microspectrometer design achieves high resolution and wide bandwidth
10. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
11. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... has named Todd Creech as Chief Financial Officer and ... Creech has been fulfilling both positions as a consultant ... http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) "Todd comes to ... leadership roles and has demonstrated great success in helping ...
... Even with radical advances in medicine and technology ... penile extender system is still the most effective ... QuickExtenderPro.com, the leading provider of penis extender ... With the emergence of the penile extender, procedures such ...
... EXTON, Pa., Feb. 11, 2011 ViroPharma Incorporated (Nasdaq: ... chief executive officer of ViroPharma, will present at the Leerink ... ET on Thursday, February 17, 2011.  The conference is being ... ViroPharma,s presentations will be webcast live for investors through ...
Cached Biology Technology:Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 2Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 3QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery 2ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference 2
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
(Date:4/18/2014)... and comet impacts can cause widespread ecological havoc, killing ... scales. But new research from Brown University shows that ... at the time of an impact. , A research ... fragments of leaves and preserved organic compounds lodged inside ... The material could provide a snapshot of environmental conditions ...
(Date:4/17/2014)... chili peppers. Information about archaeological remains of ancient chili ... appearance of words for chili peppers in ancient dialects ... highlight the value of multi-proxy data analysis. Their results ... papers presented in a special feature issue of the ... on plant and animal domestication edited by Dolores Piperno, ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Earthwatch met in Panama from Mar. 1-5 to present mid-term ... to identify and respond to the impacts of climate change. ... global team of bank employees ,climate champions, in ... program of its kind has so far: , Found ...
... $10.2 million commitment from the Robertson Foundation to create ... Duke Medicine,s pioneering cell therapy research and treatment programs ... and brain injuries suffered at birth. In making the ... Duke University, and Chief Executive Officer for Duke University ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... field, ethicists, legislators, the media and the public. ... are open to journalists and registration is free to ...
Cached Biology News:HSBC Climate Partnership yields initial research findings 2HSBC Climate Partnership yields initial research findings 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3ESHRE Annual Meeting, June 27-30 in Rome 2
... Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the fusion ... immunized (BALB/c X C57BL/6)F1 (CbyB6F1) ... mouse myeloma cellline. ...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: